TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT
FURTHER INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CHAIRMAN, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

This announcement is made by TYK Medicines, Inc (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis. Reference is also made to the Company's announcement dated September 8, 2026 (the "**September 8 Announcement**").

Dr. WU Yusheng ("**Dr. Wu**"), the chairman, executive director and chief executive officer of the Company, has informed the Company that during the period between September 8, 2026 and September 10, 2026, he has acquired 635,000 H shares of the Company on the open market (representing approximately 0.17% of the total issued share capital of the Company) at an aggregate consideration of approximately HK$2.09 million. Dr. Wu has informed the Company that he may continue to purchase shares of the Company depending on market conditions. It is currently expected that, on top of the above purchases, the total amount of the further purchases to be made by him will not exceed HK$3.0 million. Dr. Wu has stated that the acquisition of such shares is funded by his own financial resources. The further increase in shareholding demonstrates his firm belief and strong confidence in the future development prospects of the Group.

As stated in the September 8 Announcement, Dr. Wu has also undertaken to the Company that the shares of the Company acquired by him between September 8, 2026 and October 7, 2026 will all be subject to a voluntary lock-up period of six months from the respective date of purchase, during which he will not sell or otherwise transfer the relevant shares.

Based on the information available to the Company and as far as the board of directors is aware, following the increase in Dr. Wu's shareholding in the Company and as at the date of this announcement, the Company has continued to maintain sufficient public float of the issued shares in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and the increase in shareholding has been conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 10, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.